Influence of LASER therapy and Ultra-violent radiation on the treatment of diabetic foot

Phase 1

Not yet recruiting

• Conditions: Nutritional, Metabolic, Endocrine; Skin and Connective Tissue Diseases

• Registration Number: PACTR202001558172073
• Lead Sponsor: Dr. Abdulsalam Mohammed Yakasai

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2020-01-03
• Last Update Posted: 29 May 2023

Recruitment & Eligibility

• Status: Pending
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

1)Provision of signed and dated informed consent form
2)Male or Female
3)Age:18-90 years old at the time of Informed Consent (Adult, Senior)
4)Type 1 or type 2 Diabetes Mellitus
5)Presence of a diabetic foot ulcer located in the ankle area or below that has persisted a minimum of 3 months prior to the screening visit
6) Ulcer grade classified as =3 according to Wagner grading system or IA according to University of Texas Classification of Diabetic Foot Ulcers.
7) Area of ulcer (after debridement) is at least 4 cm2
8) Arterial perfusion: Patients who demonstrate adequate arterial perfusion defined as either: Ankle/brachial index (ABI) above 0.7 or that have documented confirmation of adequate arterial perfusion
9) For females of reproductive potential: use of highly effective contraception for at least 1 month prior to screening and agreement to use such a method during study participation

Exclusion Criteria

1) Pre-existing conditions - evidence of gangrene on any part of affected limb, active Charcot's foot on the study limb; infection at time of screening, deep vein thrombosis (DVT), active malignancy, being on dialysis, anemia (Hb<9 gr/dL)
2) Known allergies to dressing materials, including occlusive dressings and the adhesives on such dressings
Scheduled to undergo vascular surgery, angioplasty or thrombolysis at the time of enrollment or history of peripheral vascular repair within 10 weeks of screening
3) History of malignancy on study limb or currently receiving or has received radiation or chemotherapy within 3 months of randomization
4) Taking immunosuppressive medication
5) Received growth factor therapy (e.g., autologous platelet-rich plasma gel, becaplermin, bilayered cell therapy, dermal substitute, extracellular matrix) within two weeks of screening
6) Used oral, or IV antibiotic/antimicrobial agents or medications within 7 days of baseline
7) Has serum albumin level of<3 mg%
8) Presence of ulcers due to other causes not related to diabetes
9) HbA1c > 12% (uncontrolled hyperglycemia)
10)Pregnant at the time of screening
11) Has any photobiomodulation (low level laser) device at home

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
wound closure

Secondary Outcome Measures

Name	Time	Method
quality of life